Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
35
DERM Quote, Financials, Valuation and Earnings
Last price:
$7.82
Seasonality move
:
-10.92%
Day range:
$7.54 - $8.01
52-week range:
$3.54 - $9.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.06x
P/B ratio:
8.18x
Volume:
76.8K
Avg. volume:
220.8K
1-year change:
39.71%
Market cap:
$211.9M
Revenue:
$56.1M
EPS (TTM):
-$0.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DERM
Journey Medical Corp.
|
$18.8M | -- | 41.98% | -- | $13.50 |
|
FBIO
Fortress Biotech, Inc.
|
$21M | -$0.31 | 24.34% | -72.5% | $10.75 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DERM
Journey Medical Corp.
|
$7.81 | $13.50 | $211.9M | -- | $0.00 | 0% | 3.06x |
|
FBIO
Fortress Biotech, Inc.
|
$2.75 | $10.75 | $85.4M | -- | $0.00 | 0% | 1.29x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.06 | $0.85 | $133.6M | 1.78x | $0.80 | 0% | 2.06x |
|
OGEN
Oragenics, Inc.
|
$0.86 | $2.00 | $711.4K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DERM
Journey Medical Corp.
|
49.42% | 0.131 | 13.47% | 1.08x |
|
FBIO
Fortress Biotech, Inc.
|
55.01% | 1.103 | 55.12% | 1.93x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DERM
Journey Medical Corp.
|
$10.8M | -$1.5M | -19.67% | -44.34% | -8.67% | -$2.4M |
|
FBIO
Fortress Biotech, Inc.
|
$10.7M | -$6.8M | -56.09% | -223.06% | -38.63% | -$6.1M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Journey Medical Corp. vs. Competitors
-
Which has Higher Returns DERM or FBIO?
Fortress Biotech, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of 50.07%. Journey Medical Corp.'s return on equity of -44.34% beat Fortress Biotech, Inc.'s return on equity of -223.06%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M FBIOFortress Biotech, Inc.60.8% $0.11 $133.5M -
What do Analysts Say About DERM or FBIO?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 72.86%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 290.91%. Given that Fortress Biotech, Inc. has higher upside potential than Journey Medical Corp., analysts believe Fortress Biotech, Inc. is more attractive than Journey Medical Corp..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 FBIOFortress Biotech, Inc.1 0 0 -
Is DERM or FBIO More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.490, suggesting its more volatile than the S&P 500 by 49.031%.
-
Which is a Better Dividend Stock DERM or FBIO?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DERM or FBIO?
Journey Medical Corp. quarterly revenues are $17.6M, which are smaller than Fortress Biotech, Inc. quarterly revenues of $17.6M. Journey Medical Corp.'s net income of -$2.3M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.06x versus 1.29x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.06x -- $17.6M -$2.3M FBIOFortress Biotech, Inc.1.29x -- $17.6M $8.8M
-
Which has Higher Returns DERM or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of -255.85%. Journey Medical Corp.'s return on equity of -44.34% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About DERM or NBY?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 72.86%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Journey Medical Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Journey Medical Corp. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is DERM or NBY More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock DERM or NBY?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Journey Medical Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or NBY?
Journey Medical Corp. quarterly revenues are $17.6M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Journey Medical Corp.'s net income of -$2.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.06x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.06x -- $17.6M -$2.3M NBYNovaBay Pharmaceuticals, Inc.2.06x 1.78x $521K -$1.3M
-
Which has Higher Returns DERM or OGEN?
Oragenics, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of --. Journey Medical Corp.'s return on equity of -44.34% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About DERM or OGEN?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 72.86%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 131.36%. Given that Oragenics, Inc. has higher upside potential than Journey Medical Corp., analysts believe Oragenics, Inc. is more attractive than Journey Medical Corp..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 OGENOragenics, Inc.1 0 0 -
Is DERM or OGEN More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock DERM or OGEN?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or OGEN?
Journey Medical Corp. quarterly revenues are $17.6M, which are larger than Oragenics, Inc. quarterly revenues of --. Journey Medical Corp.'s net income of -$2.3M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.06x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.06x -- $17.6M -$2.3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns DERM or PTN?
Palatin Technologies has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of --. Journey Medical Corp.'s return on equity of -44.34% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M PTNPalatin Technologies-- -- -- -
What do Analysts Say About DERM or PTN?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 72.86%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Journey Medical Corp., analysts believe Palatin Technologies is more attractive than Journey Medical Corp..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 PTNPalatin Technologies0 0 0 -
Is DERM or PTN More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock DERM or PTN?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or PTN?
Journey Medical Corp. quarterly revenues are $17.6M, which are larger than Palatin Technologies quarterly revenues of --. Journey Medical Corp.'s net income of -$2.3M is higher than Palatin Technologies's net income of --. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.06x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.06x -- $17.6M -$2.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns DERM or TOVX?
Theriva Biologics, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of --. Journey Medical Corp.'s return on equity of -44.34% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About DERM or TOVX?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 72.86%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than Journey Medical Corp., analysts believe Theriva Biologics, Inc. is more attractive than Journey Medical Corp..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is DERM or TOVX More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock DERM or TOVX?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or TOVX?
Journey Medical Corp. quarterly revenues are $17.6M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Journey Medical Corp.'s net income of -$2.3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.06x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.06x -- $17.6M -$2.3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
